多机构比较米托蒽醌、依托泊苷和阿糖胞苷与高剂量阿糖胞苷联合米托蒽醌方案治疗复发或难治性急性髓系白血病患者
该多机构研究比较了MEC方案与Ara-C couplets方案治疗复发或难治性急性髓系白血病(R/R AML)的疗效与安全性。研究纳入155例患者,MEC组87例,Ara-C couplets组68例。两组总体缓解率无显著差异,但Ara-C couplets组更多患者桥接至异基因造血干细胞移植,且发热性中性粒细胞减少和3/4级胃肠道毒性更低。
要点
- MEC组与Ara-C couplets组总体缓解率分别为43.7%与54.4%,差异无统计学显著(P=0.10)。
- Ara-C couplets组更多患者成功进行异基因造血干细胞移植(31% vs 54.4%,P=0.003)。
- Ara-C couplets组发热性中性粒细胞减少(94% vs 72%,P<0.001)和3/4级胃肠道毒性(17.2% vs 2.94%,P=0.005)均低于MEC组。
核心结论
- 两种方案在获得总体缓解方面疗效相当,但Ara-C couplets方案与毒性显著降低相关,作者建议在R/R AML患者中更频繁地使用该方案。
研究设计与样本
- 多机构回顾性比较研究,纳入1998年至2017年间在三家学术机构治疗的155例R/R AML患者,其中87例接受MEC方案,68例接受Ara-C couplets方案。
主要发现
- 总体缓解率:MEC组43.7% vs Ara-C couplets组54.4%(P=0.10),差异无统计学显著。
- Ara-C couplets组患者更多共病(48.5% vs 33%,P=0.07)。
- Ara-C couplets组更多患者成功进行异基因造血干细胞移植(31% vs 54.4%,P=0.003)。
- 发热性中性粒细胞减少:MEC组94% vs Ara-C couplets组72%(P<0.001);3/4级胃肠道毒性:MEC组17.2% vs Ara-C couplets组2.94%(P=0.005)。
- 其他毒性及中位住院时间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compared two salvage regimens; mitoxantrone, etoposide, and cytarabine (MEC) and mitoxantrone and high-dose Ara-C (Ara-C couplets). We analyzed 155 patients treated at three academic institutions between 1998 and 2017; 87 patients received MEC and 68 received Ara-C couplets. The primary endpoint was overall response (OR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of hospitalization, hematologic and nonhematologic toxicities, and success in proceeding to alloSCT. Baseline characteristics of the cohorts were well matched, though patients receiving Ara-C couplets had more co-morbidities (48.5% vs 33%; P = .07). OR was achieved in 43.7% of MEC and 54.4% of Ara-C couplets patients (P = .10). Ara-C couplets patients also trended towards a longer OS and PFS, more frequently proceeded to alloSCT (31% vs 54.4%; P = .003), and experienced less febrile neutropenia (94% vs 72%; P < .001) and grade 3/4 gastrointestinal toxicities (17.2% vs 2.94%; P = .005). No significant differences in other toxicities or median duration of hospitalization were noted. This is the first multi-institutional study directly comparing these regimens in a racially diverse population of R/R AML patients. Although these regimens have equivalent efficacy in terms of achieving OR, Ara-C couplets use is associated with significant reductions in toxicities, suggesting it should be used more frequently in these patients.
引用
- Christian S, Arain S, Patel P, et al. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020. PMID: 32311140. doi:10.1002/ajh.25838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。